Journal
STEM CELL RESEARCH & THERAPY
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13287-021-02613-1
Keywords
Mesenchymal stem cells; Prognosis; Biomarkers; Rheumatoid arthritis; Systemic lupus erythematosus; Inflammatory bowel disease
Funding
- Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2018067/cxpy2018067]
Ask authors/readers for more resources
In this article, the research progress and clinical application of mesenchymal stem cells in chronic inflammatory systemic diseases are described, along with the search for factors and biomarkers that can predict the outcome of patients with mesenchymal stem cell transplantation.
Chronic inflammatory systemic diseases are the result of the body's immune imbalance, with a long course and recurring episodes. Immunosuppressants are the main treatment, but not all patients respond well to it. Being capable of both self-renewal and differentiation into multiple tissue cells and low immunogenicity, mesenchymal stem cell is a promising treatment for chronic inflammatory systemic diseases. In this article, we describe the research progress and clinical application of mesenchymal stem cells in chronic inflammatory systemic diseases and look for influencing factors and biomarkers that can predict the outcome of patient with mesenchymal stem cell transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available